Literature DB >> 22245306

Understanding variation in primary prostate cancer treatment within the Veterans Health Administration.

Vinod E Nambudiri1, Mary Beth Landrum, Elizabeth B Lamont, Barbara J McNeil, Samuel R Bozeman, Stephen J Freedland, Nancy L Keating.   

Abstract

OBJECTIVE: To examine the variation in prostate cancer treatment in the Veterans Health Administration (VHA)--a national, integrated delivery system. We also compared the care for older men in the VHA with that in fee-for-service Medicare.
METHODS: We used data from the Veterans Affairs Central Cancer Registry linked with administrative data and Surveillance, Epidemiology, and End Results-Medicare data to identify men with local or regional prostate cancer diagnosed during 2001 to 2004. We used multinomial logistic and hierarchical regression models to examine the patient, tumor, and facility characteristics associated with treatment in the VHA and, among older patients, used propensity score methods to compare primary therapy between the VHA and fee-for-service Medicare.
RESULTS: The rates of radical prostatectomy and radiotherapy varied substantially across VHA facilities. Among the VHA patients, older age, black race/ethnicity, and greater comorbidity were associated with receiving neither radical prostatectomy nor radiotherapy. Facilities with more black patients with prostate cancer had lower rates of radical prostatectomy, and those with less availability of external beam radiotherapy had lower radiotherapy rates. The adjusted rates of radiotherapy (39.7% vs 52.0%) and radical prostatectomy (12.1% vs 15.8%) were lower and the rates of receiving neither treatment greater (48.2% vs 32.2%) in the VHA versus fee-for-service Medicare (P < .001).
CONCLUSIONS: In the VHA, the treatment rates varied substantially across facilities, and black men received less aggressive prostate cancer treatment than white men, suggesting factors other than patient preferences influence the treatment decisions. Also, primary prostate cancer therapy for older men is less aggressive in the VHA than in fee-for-service Medicare. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22245306     DOI: 10.1016/j.urology.2011.11.013

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

1.  Understanding regional variation in Medicare expenditures for initial episodes of prostate cancer care.

Authors:  Shi-Yi Wang; Rong Wang; James B Yu; Xiaomei Ma; Xiao Xu; Simon P Kim; Pamela R Soulos; Avantika Saraf; Cary P Gross
Journal:  Med Care       Date:  2014-08       Impact factor: 2.983

2.  Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes.

Authors:  Mark V Mishra; Eli D Scher; Jocelyn Andrel; Andrew C Margules; Sarah E Hegarty; Edouard J Trabulsi; Terry Hyslop; Robert B Den; Costas D Lallas; Leonard G Gomella; Adam P Dicker; Timothy N Showalter
Journal:  Am J Clin Oncol       Date:  2015-02       Impact factor: 2.339

Review 3.  Prostate cancer in men of African origin.

Authors:  Kathleen F McGinley; Kae Jack Tay; Judd W Moul
Journal:  Nat Rev Urol       Date:  2015-12-31       Impact factor: 14.432

4.  Geographic variation in cancer-related imaging: Veterans Affairs health care system versus Medicare.

Authors:  J Michael McWilliams; Jesse B Dalton; Mary Beth Landrum; Austin B Frakt; Steven D Pizer; Nancy L Keating
Journal:  Ann Intern Med       Date:  2014-12-02       Impact factor: 25.391

5.  Treatment modalities for Māori and New Zealand European men with localised prostate cancer.

Authors:  Zuzana Obertová; Ross Lawrenson; Nina Scott; Michael Holmes; Charis Brown; Chunhuan Lao; Leanne Tyrie; Peter Gilling
Journal:  Int J Clin Oncol       Date:  2015-01-06       Impact factor: 3.402

6.  Health-Related Quality of Life and Toxicity After Definitive High-Dose-Rate Brachytherapy Among Veterans With Prostate Cancer.

Authors:  Alexander A Harris; Mayuri Yasuda; Megan S Wu; Jacqueline M Deirmenjian; Ahmer Farooq; Kristin G Baldea; Robert Flanigan; Matthew M Harkenrider; James S Welsh; Abhishek A Solanki
Journal:  Fed Pract       Date:  2021-08

7.  Treatment patterns for older veterans with localized prostate cancer.

Authors:  Richard M Hoffman; Ying Shi; Stephen J Freedland; Nancy L Keating; Louise C Walter
Journal:  Cancer Epidemiol       Date:  2015-07-27       Impact factor: 2.984

8.  American trends in expectant management utilization for prostate cancer from 2000 to 2009.

Authors:  Matthew J Maurice; Robert Abouassaly; Hui Zhu
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

9.  Design of a prostate cancer patient navigation intervention for a Veterans Affairs hospital.

Authors:  Narissa J Nonzee; June M McKoy; Alfred W Rademaker; Peter Byer; Thanh Ha Luu; Dachao Liu; Elizabeth A Richey; Athena T Samaras; Genna Panucci; XinQi Dong; Melissa A Simon
Journal:  BMC Health Serv Res       Date:  2012-09-25       Impact factor: 2.655

10.  Rural-urban differences in the clinico-pathologic profiles of Jamaican men with prostate cancer.

Authors:  William D Aiken; Kieron S Jones; Camille Ragin; Kenneth James
Journal:  Infect Agent Cancer       Date:  2015-09-28       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.